Back to Search Start Over

Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study

Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study

Authors :
Martin Köbel
Tony Panzarella
Eshetu G. Atenafu
Marcus Q. Bernardini
Sarah E. Ferguson
C. Blake Gilks
T.C. Ho
Peter F Rambau
Gregg Nelson
Blaise A. Clarke
Jessica N. McAlpine
Source :
Gynecologic Oncology. 141:559-563
Publication Year :
2016
Publisher :
Elsevier BV, 2016.

Abstract

Objective To assess the association of hormone receptor expression with outcome in high-grade endometrial carcinomas. Methods This study included three sites participating in the Canadian High Risk Endometrial Cancer (CHREC) consortium. Sections from tissue microarrays containing cases with a diagnosis of endometrioid grade 3 (EC3) and endometrial serous carcinoma (ESC) were assessed for estrogen (ER) and progesterone receptor (PR) expression by immunohistochemistry. Expression was considered present if >1% of tumor cell nuclei were labeled. Associations with overall survival were assessed. Results ER expression was present in 168/216 (78%) of EC3 and 124/192 (65%) of ESC. PR expression was present in 148/212 (70%) of EC3 and 83/196 (42%) of ESC. PR expression was significantly associated with favorable overall survival in EC3 and ESC (log rank, p =0.018 and p =0.0024) but ER expression was not. PR expression was significantly associated with favorable overall survival in EC3 independent of age, stage, center and lymph-vascular invasion (hazard ratio=0.457, 95% CI 0.257–0.811, p =0.0075) as well as in stage I and II ESC (hazard ratio=0.266, 95% CI 0.094–0.750, p =0.0123). Conclusion Our data provide support for the assessment of the PR expression status in EC3 and ESC. Future work will be required to determine how PR expression may be incorporated into management of patients with EC3 and ESC.

Details

ISSN :
00908258
Volume :
141
Database :
OpenAIRE
Journal :
Gynecologic Oncology
Accession number :
edsair.doi.dedup.....deafb9948ab75ae0c608725529426879
Full Text :
https://doi.org/10.1016/j.ygyno.2016.04.008